News | January 25, 2022

Sierra Oncology Announces Momelotinib Achieved Statistically Significant Benefit on Symptoms, Anemia and Splenic Size in the Pivotal MOMENTUM Study for Myelofibrosis —New Drug Application submission planned for second quarter of 2022— —Full data set to be presented at...

News | January 26, 2022

Sierra Oncology Announces Pricing of Upsized Public Offering of Securities SAN MATEO, Calif.–(BUSINESS WIRE)– Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, today...

News | July 22, 2021

Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTAC® Protein Degrader ARV-471 – Collaboration combines Arvinas’ investigational estrogen receptor-targeting breast cancer therapy with Pfizer’s deep experience in breast oncology...

News | June 29, 2021

ADDEX THERAPEUTICS INITIATES PIVOTAL PHASE 2B/3 STUDY WITH DIPRAGLURANT FOR DYSKINESIA ASSOCIATED WITH PARKINSON’S DISEASE Geneva, Switzerland, June 29, 2021 – Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering...

News | June 21, 2021

Sierra Oncology Announces Completion of Enrollment for MOMENTUM Phase 3 Trial—Topline data anticipated in Q1 2022 with NDA filing to follow in H2 2022— SAN MATEO, Calif., June 21, 2021 /CNW/ – Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical...

News | June 15, 2021

Braeburn Resubmits New Drug Application for BRIXADI™ (buprenorphine) Extended-Release Subcutaneous Injection for Moderate to Severe Opioid Use Disorder Plymouth Meeting, Pa. – June 15, 2021 – Braeburn announces that today the New Drug Application (NDA) for BRIXADI...